Standard BioTools Inc LAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LAB is a good fit for your portfolio.
News
-
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
-
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results
-
Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing
-
Standard BioTools to Participate in Upcoming Investor Conferences
-
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
-
Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine
-
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue
-
Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools
Trading Information
- Previous Close Price
- $2.69
- Day Range
- $2.68–2.78
- 52-Week Range
- $1.46–3.16
- Bid/Ask
- $2.66 / $2.72
- Market Cap
- $786.22 Mil
- Volume/Avg
- 1.9 Mil / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.52%
Company Profile
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 539
- Website
- https://www.standardbio.com
Comparables
Valuation
Metric
|
LAB
|
PACB
|
TIHE
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.43 | — |
Price/Sales | 2.02 | 4.74 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
LAB
|
PACB
|
TIHE
|
---|---|---|---|
Quick Ratio | 1.23 | 7.03 | — |
Current Ratio | 1.45 | 7.81 | — |
Interest Coverage | −15.25 | −21.18 | — |
Quick Ratio
LAB
PACB
TIHE
Profitability
Metric
|
LAB
|
PACB
|
TIHE
|
---|---|---|---|
Return on Assets (Normalized) | −15.05% | −15.38% | — |
Return on Equity (Normalized) | — | −41.87% | — |
Return on Invested Capital (Normalized) | — | −16.60% | — |
Return on Assets
LAB
PACB
TIHE
Diagnostics & Research Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Gjxxnkcgs | Vqhsv | $221.6 Bil | |
DHR
| Danaher Corp | Jhncrgqfx | Cjvkll | $184.9 Bil | |
IQV
| IQVIA Holdings Inc | Bycdkvz | Jdsfl | $46.0 Bil | |
IDXX
| IDEXX Laboratories Inc | Lctlwvlgms | Yqsqglc | $44.8 Bil | |
A
| Agilent Technologies Inc | Srkrchwk | Pfqvp | $42.6 Bil | |
MTD
| Mettler-Toledo International Inc | Mzjzvtcljb | Bdcpf | $28.5 Bil | |
ICLR
| Icon PLC | Gfrvqcf | Wgflqv | $27.7 Bil | |
ILMN
| Illumina Inc | Xdddrpspx | Mgkvnkp | $21.8 Bil | |
WAT
| Waters Corp | Hpdsbrxp | Dvblz | $20.4 Bil | |
LH
| Laboratory Corp of America Holdings | Kzhswzkbxj | Kmzgmh | $18.4 Bil |